JCR Pharmaceuticals Co Ltd - Company Profile
Powered by 
All the data and insights you need on JCR Pharmaceuticals Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date JCR Pharmaceuticals Co Ltd Strategy Report
- Understand JCR Pharmaceuticals Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
JCR Pharmaceuticals Co Ltd (JCR) manufactures, sells, buys, imports, and exports pharmaceutical products, regenerative drugs and drug substances. It provides biopharmaceuticals in the field of regenerative medicine for the treatment of rare diseases. The company offers pharmaceuticals to treat growth hormone deficiency, Turner syndrome, adult growth hormone deficiency, small for gestational age, renal anemia in dialysis patients, and anemia of prematurity; and a regenerative medical product for acute graft-versus-host disease and other disorders. JCR is also involved in the purchasing, selling, import and export of medical devices and laboratory instruments. It operates subsidiaries in Japan, Brazil, Switzerland and the US. JCR is headquartered in Ashiya, Hyogo, Japan.
Headquarters
Japan
Address
3-19, Kasuga-Cho, Ashiya-Shi, Hyogo, 659-0021
Website
www.jcrpharm.co.jp
Telephone
81 797 328591
No of Employees
879
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4552 (TYO)
Revenue (2022)
$253.7M
-32.8%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-74%
(2022 vs 2021)
Market Cap*
$676.0M
Net Profit Margin (2022)
XYZ
-61.3%
(2022 vs 2021)
* As of and is in US$
JCR Pharmaceuticals Co Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Pharmaceuticals | Blood-Brain Barrier Penetration Technology | Growject |
| Active Pharmaceutical Ingredients | Tissue-Targeting Technology | J-Brain Cargo |
| Pharmaceutical Raw Materials | Temcell | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In December, the company and Takeda Pharmaceutical announced a collaboration to create gene therapies by using adeno-associated viruses combined with the JCR J-Brain Cargo Technology. |
| 2023 | Contracts/Agreements | In December, the company and Modalis Therapeutics Corporation entered into an agreement to analyze the drug delivery technology of gene therapy to the central nervous system. |
| 2023 | Contracts/Agreements | In September, the company and Medipal Holdings Corp. concluded two agreements on JR-446 using JCR's proprietary J-Brain Cargo technology for the treatment of Mucopolysaccharidosis Type IIIB. |
Competitor Comparison
| Key Parameters | JCR Pharmaceuticals Co Ltd | Takeda Pharmaceutical Co Ltd | Nissan Chemical Corp | Kobayashi Pharmaceutical Co Ltd | Zeria Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Ashiya-Shi | Chuo-Ku | Chuo-Ku | Osaka-Shi | Chuo-Ku |
| State/Province | Hyogo | Tokyo | Tokyo | Osaka | Tokyo |
| No. of Employees | 879 | 49,095 | 2,965 | 3,534 | 1,729 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Shin Ashida | Chief Executive Officer; Chairman; President | Executive Board | - | - |
| Yoshio Hiyama, Ph.D. | Senior Executive Director - Production and Quality Assurance; Director - Production Division | Senior Management | - | - |
| Katsuya Daimon, Ph.D. | Director - Regulatory Affairs Department - Quality Assurance Division | Senior Management | 2021 | - |
| Yukihiro Kuromoto | Director - Murotani API Unit, Production Division | Senior Management | 2022 | - |
| Kenichi Takahashi, Ph.D. | Director - Innovative Technology Research Institute; Scientific Expert Fellow, Research Division | Senior Management | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward